Related Experiment Video
Updated: Dec 27, 2025
06:46
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
Published on: February 28, 2025
670
Beta blockers in the perioperative period.
1Department of Anaesthesia, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
British Journal of Hospital Medicine (London, England : 2005)
|February 26, 2020
Summary
Beta blockers have widespread cardiovascular effects, but their perioperative use is debated. This review examines evidence for and against their use, offering best practice guidance for patients undergoing surgery.
Area of Science:
- Cardiology
- Anesthesiology
- Pharmacology
Background:
- Beta blockers significantly impact cardiovascular function.
- Their role in the perioperative setting requires careful consideration due to potential benefits and risks.
Purpose of the Study:
- To critically evaluate the evidence supporting and refuting the perioperative use of beta blockers.
- To provide evidence-based guidance for optimal clinical practice.
Main Methods:
- Review of existing literature on beta blocker efficacy and safety in the perioperative period.
- Analysis of clinical trial data and observational studies.
Main Results:
- Evidence suggests both benefits and potential harms of perioperative beta blockers, depending on patient factors and specific agents.
- The optimal strategy for initiating or continuing beta blockers is not definitively established.
Conclusions:
- Perioperative beta blocker management should be individualized.
- Further research is needed to clarify best practices for specific patient populations and surgical contexts.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
01:28Antihypertensive Drugs: Types of β-Blockers
1.4K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:22Heart Failure Drugs: β-Blockers
684
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
684
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K